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Background: HIV-1 Tat activates RNA Polymerase II (RNAP II) elongation of the integrated provirus by recruiting a
protein kinase known as P-TEFb to TAR RNA at the 50 end of nascent viral transcripts. The catalytic core of P-TEFb
contains CDK9 and Cyclin T1 (CCNT1). A human endogenous complexome has recently been described – the set of
multi-protein complexes in HeLa cell nuclei. We mined this complexome data set and identified 12 distinct
multi-protein complexes that contain both CDK9 and CCNT1. We have termed these complexes CCAPs for CDK9/
CCNT1-associated protein complexes. Nine CCAPs are novel, while three were previously identified as Core P-TEFb,
the 7SK snRNP, and the Super-Elongation Complex. We have investigated the role of five newly identified CCAPs in
Tat function and viral gene expression.
Results: We examined five CCAPs that contain: 1) PPP1R10/TOX3/WDR82; 2) TTF2; 3) TPR; 4) WRNIP1; 5) FBXO11/
CUL1/SKP1. SiRNA depletions of protein subunits of the five CCAPs enhanced Tat activation of an integrated HIV-1
LTR-Luciferase reporter in TZM-bl cells. Using plasmid transfection assays in HeLa cells, we also found that siRNA
depletions of TTF2, FBXO11, PPP1R10, WDR82, and TOX3 enhanced Tat activation of an HIV-1 LTR-luciferase reporter,
but the depletions did not enhance expression of an NF-κB reporter plasmid with the exception of PPP1R10. We
found no evidence that depletion of CCAPs perturbed the level of CDK9/CCNT1 in the 7SK snRNP. We also found
that the combination of siRNA depletions of both TTF2 and FBXO11 sensitized a latent provirus in Jurkat cells to
reactivation by sub-optimal amounts of αCD3/CD28 antibodies.
Conclusions: Our results identified five novel CDK9/CCNT1 complexes that are capable of negative regulation of
HIV-1 Tat function and viral gene expression. Because siRNA depletions of CCAPs enhance Tat function, it is possible
that these complexes reduce the level of CDK9 and CCNT1 available for Tat, similar to the negative regulation of
Tat by the 7SK snRNP. Our results highlight the complexity in the biological functions of CDK9 and CCNT1.Background
A critical step in the HIV-1 replication cycle is transcrip-
tion of the integrated provirus by RNA polymerase II
(RNAP II). Although RNAP II initiates transcription from
the HIV-1 LTR at a relatively high basal rate, the polymer-
ase stalls after synthesis of a short transcript due to the ac-
tion of two negative elongation factors, NELF and DSIF,
which associate with the RNAP II complex and inhibit
elongation [reviewed in [1-4]]. Pausing of RNAP II elong-
ation is also seen in cellular genes and serves as a quality* Correspondence: arice@bcm.edu
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distribution, and reproduction in any mediumcontrol mechanism to enable efficient capping of the 50
end of the mRNA [5,6]. In the case of HIV-1, the viral Tat
protein recruits a cellular protein kinase complex termed
P-TEFb to the TAR RNA element that forms at the 50 ends
of the nascent viral transcript. The catalytic component of
P-TEFb is composed of CDK9 as the catalytic subunit and
a Cyclin regulatory subunit, either Cyclin T1 (CCNT1) or
Cyclin T2 (CCNT2). P-TEFb activates transcriptional
elongation by phosphorylating the carboxyl terminal do-
main (CTD) of the large subunit of RNAP II; P-TEFb also
phosphorylates specific protein subunits of NELF and
DSIF, and this negates their inhibition of elongation. For
cellular genes, P-TEFb can be recruited to the RNAP II
complex by different mechanisms to stimulate elongation.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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P-TEFb and directs P-TEFb to actively transcribed genes
that are marked by acetylated histones [7-9]. Transcription
factors that bind directly to DNA elements in cellular pro-
moters, such as NF-κB, cMyc, and MEF2, can also recruit
P-TEFb to active genes [10-12].
P-TEFb is known to exist in three distinct complexes:
1) the “Core” complex composed of CDK9/CCNT1 or
CCNT2/BRD4; 2) the “7SK snRNP” complex composed
of CDK9/CCNT1 or CCNT2/7SK snRNA/ HEXIM1 or
HEXIM2/LARP7/ MEPCE; 3) “Super Elongation Com-
plex” (SEC) composed of CDK9/CCNT1 or CCNT2/
ELL2/AFF4/ENL/AF9 [4]. Gel filtration analyses of puri-
fied Flag-tagged CDK9 have confirmed that these three
complexes exist as distinct biochemical entities [13].
CDK9 kinase activity is repressed in the 7SK snRNP, and
this complex is not thought to directly activate tran-
scriptional elongation. Rather, the 7SK snRNP may be a
catalytically inactive pool of P-TEFb from which active
P-TEFb can be recruited to function in either the Core
or SEC P-TEFb complex to activate elongation [14].
Consistent with this idea, disruption of the 7SK snRNP
by siRNA depletions of HEXIM1 results in increased
levels of Tat activation of the viral LTR [15].
The HIV Tat protein binds directly to CCNT1 and
thereby targets only CCNT1-containing P-TEFb com-
plexes [16]. Tat is capable of utilizing the Core P-TEFb
complex by displacing Brd4 from CDK9/CCNT1 [17].
Tat can trigger the release of CDK9/CCNT1 from the
7SK snRNP and utilize this P-TEFb complex [18-20]. Tat
also associates with the SEC and stabilizes this P-TEFb
complex to activate viral gene expression [21,22].
Nearly all cellular processes are carried out by multi-
protein complexes [23,24]. A recent study using a high-
throughput integrative mass spectrometry-based analysis
described the human endogenous complexome – the set
of multi-protein complexes in HeLa cells [25]. In this
landmark study, 1,796 primary antibodies were used in
3,390 immunoprecipitations of HeLa cell nuclear extracts.
Conditions of immunoprecipitations were developed to
preserve weak protein interactions and high levels of reci-
procity in affinity purifications were used to identify dis-
tinct multi-protein complexes. We have mined this data
set to identify multi-protein complexes that contain
CDK9 and CCNT1. The three known P-TEFb complexes
– Core, 7SK snRNP and SEC – as well as nine additional
CDK9/CCNT1 complexes were identified in this analysis.
In this study, we focused on five of these novel complexes
and found that siRNA depletion of protein subunits of
these novel complexes enhanced HIV-1 Tat function and
viral gene expression. Although the mechanisms whereby
siRNA disruption of these novel CDK9/CCNT1 com-
plexes stimulate Tat function remain to be elucidated, our
data suggest that their disruption may increase the level ofP-TEFb available for Tat to utilize, similar to disruption of
the 7SK snRNP. Our study indicates that the complexity
of P-TEFb is considerably greater than previously
appreciated.
Results
Identification of novel CDK9/CCNT1-associated proteins
(CCAPs)
We mined the recently described human complexome
dataset [25] to identify distinct protein complexes that con-
tain both CDK9 and CCNT1. As shown in Figure 1, this
analysis identified previously reported and novel CDK9/
CCNT1-containing complexes. We refer to these com-
plexes as CCAPs, for CDK9/CCNT1-associated protein
complexes. Two CCAPs are mutually exclusive in our data
set – HEXIM1/LARP7/MEPCE (complex B) and BRD4
(complex C). The identification of these mutually exclusive
CCAPs agrees precisely with traditional experimental
approaches that identified these two distinct CDK9/
CCNT1 complexes [26]. Additionally, the recently identi-
fied Super-elongation complex (SEC) complex (AFF4/
AFF1/MLLT1/ELL2/MLLT3/; complex D [21,22,27]) was
identified in our analysis, further validating this experimen-
tal approach to identify CCAPs of likely relevance to cellu-
lar and HIV-1 gene expression.
A prominent CCAP not shown in Figure 1 due to size
constraints contains CDK9/CCNT1 in a very large multi-
protein complex that regulates transcription initiation and
chromatin remodeling [CBP/p300; the 15 subunit INO80
complex; 20 subunit SWI/SNF complex; 30 subunit Medi-
ator (Mediator has been implicated in HIV-1 replication
in siRNA screens [28]). Two CCAPs involved in transcrip-
tion elongation are prominent in Figure 1: AFF4/AFF1/
MLLT1/ELL2/MLLT3 (Super-Elongation complex D) and
WDR82/PPP1R10/TOX3 (complex E) that interacts with
the LEO1/PAF complex (histone methyltransferase activ-
ity) and is implicated in transcriptional elongation [25].
TTF2 (complex G) is a CCAP involved in RNA Polymer-
ase II termination. Two CCAPs associate with nuclear
pores, RANGAP1 (complex H) and TPR (complex I).
Other CCAPs included the checkpoint module ATR/
ATRIP (complex J), ubiquitin binding protein WRNIP1
(complex K), and SCFFBXO11 ubiquitin E3 ligase (complex
L). The proteins PRPF8 (complex F) and RANBP2 (com-
plex H) have been implicated in HIV-1 replication in
siRNA screens [28]. The identification of novel CCAPs
involved in RNA elongation, RNA splicing, transcription
termination, and nuclear pores suggest that the role of
CDK9/CCNT1 in cellular and HIV-1 gene expression is
considerably more intricate than previously appreciated.
SiRNA depletion of CCAPs
To begin to investigate if CCAPs are involved in HIV-1
Tat function, we used siRNAs to deplete protein
Figure 1 CCAPs identified from human complexome. The indicated CCAPs were derived from an integrative mass spectrometry analysis of a
large scale immunoprecipitation study [25]. The range of spectral counts (SPCs; number of peptides identified by mass spectrometry) for proteins
in CCAPs is indicated by a gray scale. Antisera used for each immunoprecipitation experiment are indicated at the top of the figure and can be
found in Supplemental Information of reference 25. Arrows indicate the five CCAPs investigated in this study.
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assays for the effects of depletions of protein subunits of
the five CCAPs indicated by arrows in Figure 1 sug-
gested that these CCAPs negatively regulate Tat func-
tion. We therefore focused on these five CCAPs in this
study. The properties of protein subunits of these five
CCAPs are summarized in Table 1.
We used the TZM-bl cell line for our depletion experi-
ments; this cell line is a HeLa cell derivative that
expresses CD4, CXCR4, and CCR5 on its cell surface
and therefore can be infected by HIV-1 [40]. TZM-bl
cells also contain an integrated copy of the HIV-1 LTR
with a Luciferase reporter protein. Tat transactivation
assays can be readily performed in TZM-bl cells by
transfection of a Tat expression plasmid andmeasurement of Luciferase expression from the inte-
grated provirus. As the human complexome data set
was generated in HeLa cells [25], the CCAPs shown in
Figure 1 are likely similar if not identical between TZM-
bl and HeLa cells.
In the experiment shown in Figure 2A and 2B, TZM-
bl cultures were transfected with siRNAs directed
against either TTF2 (Figure 1, complex G), TPR (com-
plex I), WRNIP1 (complex K), or FBXO11 (subunit of
complex L). Cell lysates were prepared 72 hours after
siRNA transfections, and the degrees of protein deple-
tion were analysed by immunoblots. SiRNAs against
TPR was effective in depleting TPR but had no effect on
WRNIP1, TTF2, or FBXO11 (Figure 2A). SiRNAs
against TTF2 effectively depleted TTF2 but had no
Table 1 Protein subunits of CCAPs depleted in this study
Protein
depleted
CCAP Name Other names Function of depleted protein Reference
FBXO11 FBXO11 F-box protein 11 UBR6;VIT1; FBX11; PRMT9;
UG063H01
Phosphorylation-dependent ubiquitination, regulates p53
and BCL6
[29,30]









Targets protein phosphatase-1 (PP1) to the nucleus, in DNA
damage response
[31]
WDR82 PNUTS WD repeat domain 82 SWD2; MST107; WDR82A;
MSTP107; PRO2730;
TMEM113; PRO34047
Component of the mammalian SET1A /SET1B histone H3-
Lys4-methyltransferase complexes
[32]
TOX3 TOX high mobility
group box family
member 3
CAGF9; TNRC9 Unwinding of DNA, chromatin structure alteration and
neuronal transcription
[33]
TPR TPR Translocated promoter
region (to activated
MET oncogene)
Directly interacts with several components of nuclear pore






HuF2 Critical role in altering protein-DNA interactions. Has dsDNA-
dependent ATPase and RNAPII termination activity. Plays a
role in pre-mRNA splicing.
[35,36]




Interacts with the N-terminal portion of Werner protein
containing the exonuclease domain and implicated in
Werner’s syndrome. It may influence aging process.
[37-39]
The proteins that were depleted using siRNA in this study are listed. The core complex these proteins exist in cells as presented in Figure 1 is included along with
brief description of their cellular function.
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NAs against FBXO11 were effective against FBXO11 but
had no effect on WRNIP1 or TTF2 (Figure 2B). SiRNAsFigure 2 SiRNA depletions of protein subunits of CCAPs. TZM-bl cells
proteins for 72 hours. Cell lysates were prepared, and protein expression w
(A) Panel shows expression of TPR in cells transfected with control or siRNA
show expression level of TTF2 and FBXO11, respectively, in cells transfected
Panels show expression of WRNIP1 and PPP1R10 in cells transfected with s
viability following transfection of control or PP1R10 siRNAs; the data are th
normalized to 100.transfected in TZM-bl cells against WRNIP1 (complex
K) and PPP1R10 (complex E) were also effective in de-
pleting the target protein (Figure 2C, 2D). These datawere transfected with control siRNA or siRNAs against indicated
as analysed by immunoblots. β-actin was used as a loading control.
against TPR, WRNIP1, TTF2 and FBXO11; (B) Top and middle panels
with control or siRNA against WRNIP1, TTF2 or FBXO11; (C and D)
iRNAs against WRNIP1 and PPP1R10, respectively. (E) Graph shows cell
e average of three independent experiments with viability of control
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geted subunits of these CCAPs.
Because PPR1R10 is associated with Protein Phosphat-
ase 1 and regulates the activity of a cellular enzyme that
regulates many cellular processes, we monitored the ef-
fect of siRNA depletion of PPP1R10 on cell viability
using a Trypan Blue exclusion assay. TZM-bl cells were
transfected with siRNAs against PPP1R10 or control siR-
NAs. Cells were collected at 72 hours post-transfection
and divided into two groups – one group was lysed, and
depletion of PPP1R10 was verified by immunoblot (data
not shown); and the other group was assayed for cell
viability. As shown in Figure 2E, there was only a small
reduction in the viability of the cells depleted of
PPP1R10 compared to control siRNA-treated cells. This
small reduction in cell viability by siRNA depletion of
PP1R10 is unlikely to explain the enhancement of Tat
function by the depletion (see below).
SiRNA depletion of CCAPs enhances Tat activation of
HIV-1 LTR
To examine the functional effects of depletions of pro-
tein subunits of CCAPs, TZM-bl cells were transfected
with siRNAs, followed by transfection of expression
plasmids for either wild type Tat (wtTat) or the
transactivation-defective mutant termed Pro18IS Tat
(mTat) [41]. Cell lysates were prepared 24 hours after
Tat plasmid transfections and analysed for Luciferase ex-
pression from the integrated HIV-1 LTR in TZM-bl
cells. Additionally, siRNAs against CCNT1 were trans-
fected as a control in which Tat function should be
reduced. When compared with transfection of control
siRNAs, the depletion of CCNT1 inhibited activation of
the integrated HIV-1 LTR Luciferase reporter by the
wtTat protein as expected (Figure 3A, C). Depletion of
subunits of each CCAP examined — TPR, WRNIP1,
TTF2, FBOX11, PPP1R10, WDR82, TOX3 – increased
activation by the wtTat protein that was statistically sig-
nificant in a Student’s T-test (Figure 3A, C, E). Depletion
of the individual subunits of the PPP1R10 complex –
PPP1R10, WDR82 and TOX3 – also increased activation
by wt Tat to a statistically significant level, from approxi-
mately 3- to 10-fold (Fisgure 3A). TTF2 and FBXO11
depletion activated the HIV-1 LTR Luciferase reporter
by approximately 3- and 2-fold, respectively (Figure 3C),
while depletion of TPR and WRNIP1 resulted in activa-
tion by approximately 3- and 2-fold, respectively, relative
to control siRNAs (Figure 3E). We obtained similar
results as those shown with wt Tat in Figure 3 with
siRNA depletions of CCAPs in Jurkat T cells infected
with an HIV-1 luciferase reporter virus, although the
magnitude of Tat enhancement was less than that seen
in TZM-bl cells (data not shown), likely due to ineffi-
cient siRNA transfections and depletions in Jurkat cells.In cells transfected with transactivation-defective mTat
plasmid, depletion of TPR, WRNIP1, TTF2, FBXO11,
and WDR82 also resulted in an induction HIV-1 LTR-
driven Luciferase expression, although the level of Luci-
ferase expression was considerably less than cells trans-
fected with wtTat (Figure 3B, D, F). These data suggest
that disruption of the five newly identified CCAPs by
siRNA depletions enhances Tat activation of the HIV-1
LTR, perhaps by increasing the pool of CDK9/CCNT1
that is available for Tat function.
Based on the results shown in Figure 3, it is conceiv-
able that the five CCAPs examined could function addi-
tively to regulate Tat function. Therefore, we evaluated
the effects of depletions of combinations of CCAPs on
Tat transactivation in TZM-bl cells (Additional file 1:
Figure S1). This analysis demonstrated that some combi-
nations showed a strong additive effect on increasing Tat
transactivation, especially the combination of TTF2 and
FBXO11.
Activation of NF-κB is not responsible for the increase of
HIV-1 gene expression upon depletion of CCAPs
It is possible that the enhancement of viral gene expression
by siRNA depletions of CCAPs may involve activation of
NF-κB arising from a stress response to the depletions. To
investigate this possibility, we carried out plasmid transfec-
tion assays with HIV-1 LTR and NF-κB Luciferase reporter
plasmids in HeLa cells. Cultures were transfected with con-
trol or specific siRNAs, and 48 hours later cells were co-
transfected a HIV-LTR Luciferase reporter plasmid plus a
wtTat plasmid Tat or a NF-κB Luciferase reporter plasmid
plus the CMV parental vector. Cell lysates were prepared
24 hours post-plasmid transfection, and Luciferase expres-
sion was measured (Figure 4). As expected, depletion of
CCNT1 reduced expression of the HIV-1 LTR, while deple-
tion of CCAPs (TTF2, FBXO11, PPP1R10, and WDR82,)
enhanced viral LTR expression. Depletion of CCNT1
reduced expression from the NF-κB reporter, while deple-
tion of all CCAPs other than PPP1R10 also reduced expres-
sion of the NF-κB reporter. These data indicate that
depletion of CCAPs does not increase HIV LTR-directed
gene expression through activation of NF-κB with the pos-
sible exception of PPP1R10.
Enhancement of Tat activation by CCAP depletions is not
the result of increased Tat protein expression or
increased release of CDK9/CCNT1 from 7SK snRNP
It is possible that siRNA depletions of CCAPs results in
increased Tat protein levels from the Tat expression plas-
mid, and this might contribute to increased Tat function
in TZM-bl cells. To investigate this possibility, we trans-
fected HeLa cells with control siRNA or siRNA against
CCNT1, HEXIM1, or PPP1R10, followed by transfection
of the Flag-tagged wild type HIV-1 Tat expression
Figure 3 Effects of siRNA depletions of CCAPs on Tat transactivation. TZM-bl cells were transfected in triplicate with control siRNA or
indicated siRNAs. 48 hours later, cells were transfected with expression plasmid for wild-type Tat (wtTat) (A, C and E) or transactivation-defective
mutant Pro18IS Tat (mTat) (B, D and F). Luciferase expression from the integrated HIV-1 LTR was measured 24 hours post-plasmid transfection
and normalized to total cellular protein. A representative experiment is shown from three independent experiments. Statistical significance was
estimated using Student’s t-test. (* p≤ 0.05 and ** p< 0.005). Note the difference in scales between panels A, C, E and B, D, F.
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as its depletion resulted in relatively high levels of en-
hancement of Tat activation (see Figure 3A and Figure 4).
Cell lysates were prepared 24 hours post-plasmid transfec-
tion, and protein levels were analysed by immunoblot
(Figure 5A). SiRNAs were effective in depletion of CCNT1
and PPP1R10, while depletion of HEXIM1 was somewhat
less efficient. We did not observe a significant difference
in the expression of Flag-Tat upon between the PPP1R10
depletion and control siRNA-treated cells (Figure 5A), al-
though Tat activity was enhanced under these conditionsof PPP1R10 depletion (Figures 3A, 4). This result suggests
that depletion of CCAPs enhances Tat function through
mechanisms other than increasing Tat levels from the
plasmid vector.
We also investigated whether depletion of CCAPS
might affect the amount of CDK9/CCNT1 in the 7SK
snRNP. Depletion of TTF2 and FBXO11 was used for this
control experiment because this combination of CCAP
depletions showed the greatest level of Tat enhancement
observed in this study (see Additional file 1: Figure S1).
HeLa cells were first transfected with a combination of
Figure 4 Enhancement of Tat activation by CCAP depletions is not due to activation of NF-κB. HeLa cells were transfected for 48 hours
with control siRNA or the indicated siRNAs. Cells were then co-transfected with 500 ng HIV-1 LTR-Luciferase reporter plasmid plus 50 ng wtTat
plasmid or 500 ng NF-κB-Luciferase reporter plasmid plus 50 ng pCMV parent vector. Cell extracts were prepared 24 hours post-plasmid
transfection, and Luciferase expression was normalized to total cellular protein in cell extracts. Statistical significance was determined using a
t-test. A representative experiment from three independent experiments is shown (* represents p value ≤0.05).
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hours later cells were transfected with expression plasmids
for Flag-tagged wild type Tat or mutant Tat and HA-
CCNT1; 48 hours later cell extracts were prepared for
immunoprecipitations with an antiserum against CDK9.
As shown in Figure 5B, no difference in the association of
CDK9 with CCNT1 or HEXIM1 was observed in cells
transfected with Flag-tagged wild type and mutant TatFigure 5 Enhancement of Tat activation by CCAP depletions is not du
CCNT1 with 7SK/HEXIM1. (A) HeLa cells were transfected with indicated
HIV-1 Tat expression plasmid. At 24 hours post-plasmid transfection, cell lys
expression levels of Flag-Tat, CCNT1, HEXIM1 and PPP1R10; β-actin was pro
TTF2+ FBXO11 siRNAs and 48 hours later transfected with expression plasm
for a further 48 hours. Cell lysates were prepared and immunoprecipitated
shows the immunoprecipitated proteins.and treated with either control or TTF2+ FBXO11 siR-
NAs. This result suggests that depletion of CCAPs does
not affect the level of CDK9/CCNT1 in the 7SK snRNP.
Combination of TTF2 and FBXO11 depletion sensitizes
Jurkat CD4+ T cells to reactivation of latent HIV-1
The results presented above indicate that depletion of
CCAPs increases Tat function and HIV-1 gene expression.e to increased Tat expression or differential association of CDK9/
siRNAs for 48 hours followed by transfection of Flag-tagged wild type
ates were prepared and immunoblot analysis carried out for
bed as loading control. (B) HeLa cells were transfected with control or
ids for HA-CCNT1 or Flag-wild type Tat (wtTat) or mutant Tat (mTat)
with CDK9. Left part of the panel shows input levels, and right part
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have an effect on reactivation of a latent HIV-1 provirus.
We used the Jurkat 2D10 cell line for this experiment;
2D10 cells contain a latent provirus virus with a destabi-
lized eGFP in place of Nef [42]. When treated with αCD3/
CD28 beads, activation of the latent provirus can be
examined by flow cytometry. We evaluated depletion of
TTF2 + FBXO11 in this experiment, as this combination
of depletion has the strongest enhancement of TatFigure 6 Depletions of TTF2 and FBXO11 sensitize latent provirus in J
were transfected with control siRNA or siRNA against TTF2 and FBXO11 for
CD3/CD28 beads and GFP expression from re-activated provirus was analys
independent experiments is shown. (A) The panel shows GFP expression in
treated with either control siRNA or TTF2 and FBXO11 siRNA at the indicate
placeholder fluorophore to enable visualization as a dot plot. A representat
samples is shown. (B) The graph represents average GFP expression in cell
represent background GFP expression. Statistical significance was computeactivation in TZM-bl cells (Additional file 1: Figure S1).
2D10 cells were transfected with control siRNA or siRNAs
against TTF2 and FBXO11. Thirty six hours post-siRNA
transfection, cells were treated with sub-optimal amounts
of αCD3/CD28 beads, and GFP expression was monitored
by flow cytometry 16 and 24 hours later. Depletion of
both TTF2 and FBXO11 resulted in an increase in
the number of GFP+ cells relative to the control siRNA
(Figure 6). At 16 hours post-activation, the TTF2/FBXO11urkat 2D10 cell line to re-activation. Duplicate Jurkat 2D10 cultures
36 hours. Cells were then activated with suboptimal amounts (2μl) of
ed by flow cytometry. A representative experiment from two
untreated cells (background GFP expression) and in activated cells
d time points. The x-axis is GFP, and the y-axis is PE that is used as a
ive flow cytometric analysis of GFP expression from the duplicate
s that were transfected with indicated siRNA. The untreated cells
d using the t-test (* represent p≤ 0.05 and ** represents p< 0.005).
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depletions demonstrated 27%. At 24 hours post-activation,
27% of cells depleted for both TTF2 and FBXO11
remained GFP+, while only 21% of cells transfected with
control siRNAs were GFP+. These differences at 16 and
24 hour post-activation between the TTF2/FBXO11 and
control siRNA depletions were statistically significant as
determined by a t-test (p values < 0.005 and 0.05, respect-
ively). This result is consistent with the data presented in
Figures 3, 4 and Additional file 1: Figure S1 that indicate
that depletion of the five CCAPs evaluated in this study
enhances HIV-1 gene expression. Similar to depletion of
HEXIM1 in the 7SK snRNP, it is possible that depletion of
these CCAPs enhances viral gene expression by increasing
the levels of CDK9/CCNT1 available for Tat function.
Discussion
The production of cellular mRNA and HIV-1 RNA from
the integrated provirus is a highly regulated process in
which the individual steps are linked. RNA splicing is
coupled to transcriptional elongation [43], and nuclear
export of processed RNA can be affected by splicing
[44]. Most, if not all proteins responsible for production
of RNA exist in multi-protein complexes, and the under-
standing of mechanisms involved in HIV-1 RNA pro-
duction will require the identification of protein
complexes involved in the individual steps of viral RNA
production. In this study, we mined the recently
described HeLa cell nuclear complexome [25] to investi-
gate multi-protein complexes involved in HIV-1 Tat
function and viral gene expression. Our analysis of the
complexome data set identified 12 multi-protein com-
plexes which contain CDK9/CCNT1, the enzymatic core
of the general RNAP II elongation factor known as P-
TEFb that mediates Tat transactivation. Our analysis
identified the three previously known CDK9/CCNT1
complexes –Core, 7SK snRNP, and SEC P-TEFb com-
plexes [4], thereby validating our analytical approach.
We identified nine additional multi-protein complexes
that contain CDK9/CCNT1; eight of these novel CDK9/
CCNT1 complexes are shown in Figure 1, while the lar-
gest complex identified (not shown in Figure 1) contains
CBP/p300, the 15 subunit INO80 complex, 20 subunit
SWI/SNF complex, and 30 subunit Mediator complex.
We have termed these multi-protein complexes CCAPs
for CDK9/CCNT1-associated protein complexes.
To begin to investigate the role of novel CCAPs in Tat
function, we carried out siRNA depletions of protein
subunits of five CCAPs. We chose to focus on these five
CCAPs in the present study as our initial results indi-
cated that depletions of their protein subunits enhanced
Tat function. We found that disruption of these CCAPs
by siRNA depletions resulted in enhanced Tat function
in TZM-bl cells. Because previous work has shown thatdepletion of HEXIM1 in the 7SK snRNP enhances Tat
function by increasing the available pool of CDK9/
CCNT1, we favour the hypothesis that depletion of these
five CCAPs enhances Tat function by also increasing the
available pool of CDK9/CCNT1. However, future studies
will be required to determine the molecular mechanisms
whereby disruption of these five CCAPs enhances Tat
function. Our initial results with a CCAP containing
ATR/ATRIP (Complex J, Figure 1) indicated that deple-
tion of these proteins inhibits Tat function, consistent
with a previous study [45]. Additionally, it is likely that
depletion of subunits of the largest CCAP (CBP/p300,
the 15 subunit INO80 complex, 20 subunit SWI/SNF
complex, and 30 subunit Mediator complex) will inhibit
Tat, as some of these protein subunits have been shown
to play a positive role in Tat function and HIV-1 replica-
tion [28,46,47].CCAPs examined in this study
The protein subunits of the CCAPs examined here have
been previously shown to be involved in a number of
cellular processes of interest to cellular and HIV-1 RNA
metabolism. The finding that these proteins associate
with CDK9/CCNT1 has a number of intriguing func-
tional and mechanistic implications. Short descriptions
of the known functions of the protein subunits of these
CCAPs are presented below.PPP1R10/TOX3/WDR82
Complex E (Figure 1) recruits the phosphatase PP1 into
the nucleus and is involved in the DNA damage re-
sponse [31,48]. Additionally, WDR82 is found in the
SET1A histone H3-Lys4-methyltransferase complex [32]
and this chromatin modification in associated with ac-
tively expressed genes.TTF2
This CCAP subunit is involved in the termination of
RNAP II transcription [35]. TTF2 has also been implica-
tion in mitotic repression of transcriptional elongation
[36]. A recent publication reported that TTF2 is asso-
ciated with decapping factors and the Xrn2 exonuclease
at transcriptional start sites and is involved in premature
termination of RNAP II transcription [49].TPR
This CCAP subunit is a large coiled-coiled protein and
is localized within the nuclear basket of the nuclear pore
complex; TPR plays a role in nuclear export of mRNA
[34,50]. Fusion of the 50 end of the TPR gene with sev-
eral different kinase genes is associated with cancer.
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This CCAP subunit interacts with the Werner protein
and is implicated in Werner’s syndrome [37]. The Wer-
ner protein is involved in RNAP II transcription and its
dysfunction in Werner’s syndrome results in an acceler-
ated aging phenotype [38].
FBXO11/CUL1/SKP1
This CCAP is involved in phosphorylation-dependent
ubiquitylation of target proteins and has been shown to
regulated BCL6 and p53 [29,30].
Complexity of P-TEFb and CCAPs
The identification of 12 CCAPs in this study and the het-
erogeneity in the catalytic core of P-TEFb reveal an enor-
mous potential complexity in the biological functions of
CDK9 and CCNT1. The catalytic core is composed of a
heterodimer of CDK9 and a Cyclin subunit, either
CCNT1 or CCNT2 [3]. Additionally, two spliced variants
of CCNT2 are expressed, CCNT2a and CCNT2b [51], as
are two isoforms of CDK9, a major 42 kDa isoform and a
minor 55 kDa isoform that arises from an upstream tran-
scriptional start site [52]. It is possible that these two
CDK9 isoforms may differentially associate with the
CCAPs shown in Figure 1, and it is possible that one or
both of the CCNT2 isoforms may replace CCNT1 in these
multi-protein complexes. Complexes that differ by their
CDK9 or Cyclin subunit may have distinct functional
properties, as well as distinct expression patterns in differ-
ent tissues. Transcriptional profiling of cells depleted for
either CCNT1 or CCNT2 has identified mRNAs whose
expression patterns appear dependent on either CCNT1
or CCNT2 [53,54]. The expression pattern of the 42 kDa
and 55 kDa CDK9 proteins varies across different murine
tissues, with liver having higher expression of the 55 kDa
protein than the 42 kDa protein [55]. The 55 kDa, but not
42 kDa, CDK9 protein has also been shown to accumulate
in the nucleolus of HeLa cells [56].
Regulation of in CCAPs in CD4+ T lymphocytes and
monocytes/macrophages
The expression patterns of the protein subunits of CCAPs
in CD4+ T cells and monocytes/macrophages have import-
ant implications for HIV-1 replication, as these are the two
major cell types infected by HIV-1 in vivo. Resting CD4+ T
cells do not support HIV-1 replication, in part because P-
TEFb function is limiting [57,58]. In resting CD4+ T cells,
CCNT1 levels are low, and this involves repression
of translation of CCNT1 mRNA by miRNAs [59]. Upon T
cell activation, this repression is released and there is a
strong induction of CCNT1 protein levels [60-62]. In rest-
ing CD4+ T cells, the catalytic function of CDK9 is further
repressed by dephosphorylation of T186 in the T-loop of
the kinase; upon T cell activation there is a rapid inductionof T-loop phosphorylation and CDK9 kinase activity
[63,64]. Also in resting CD4+ T cells, the level of the 7SK
snRNP complex is low, and upon T cell activation there is a
large increase the level of the 7SK snRNP [65,66]. In pre-
liminary experiments, we found that the protein subunits
of the five CCAPs investigated in this study are expressed
at low level in resting CD4+ T-cells and are induced upon
cellular activation, suggesting that the levels of these
CCAPs are up-regulated following T cell activation. Thus, it
appears that resting CD4+ T cells require only very low
levels of CCAPs to support basal metabolism in quiescent
T cells.
Similarly, CDK9 and CCNT1 are highly regulated in
monocytes and macrophages. In monocytes, miR-198
represses expression of CCNT1 [67] and although the
42 kDa CDK9 protein is generally expressed at a high
level, the CDK9 T-loop is not phosphorylated [68]. Upon
macrophage differentiation, CCNT1 levels are strongly
up-regulated and the CDK9 T-loop is phosphorylated
[68-70]. The 55 kDa CDK9 protein is also up-regulated
during macrophage differentiation [56]. Similar to rest-
ing and activated CD4+ T cells, the 7SK snRNP complex
is expressed at only low levels in quiescent monocytes
and it is induced following macrophage differentiation
[71]. Upon extended time in culture, CCNT1 expression
is shut-off by proteasome-mediated proteolysis [69].
However, CCNT1 but not CCNT2 expression can be
up-regulated in late differentiated macrophage by either
HIV-1 infection or activation with pathogen-associated
molecular patterns (PAMPs). With the exception of Core
P-TEFb and the 7SK snRNP, the expression patterns of
CCAPs shown in Figure 1 have not been examined in
monocytes and macrophages.
Future studies
Four of the novel CCAPs identified by our analysis re-
main to be investigated for potential roles in Tat function
(Figure 1, complexes F, H, J, and the CBP/p300, the 15
subunit INO80 complex, 20 subunit SWI/SNF complex,
and 30 subunit Mediator complex). Our preliminary
results with the ATR/ATRIP CCAP suggest that it may
act to positively regulate Tat function and viral gene ex-
pression, in agreement with a previous study [45]. ATR is
a protein kinase involved in the DNA damage response,
and it is activated by the HIV-1 Vpr protein [72]. The
finding that ATR/ATRIP is found in a complex with
CDK9/CCNT1 raises the intriguing possibility of a mech-
anistic link between Tat and Vpr functions. Complex H
contains RNAGAP1/RANBP2/RFPD3 and is involved in
nuclear pore function, suggesting that Tat activation of
RNAP II elongation may be coupled to RNA export and
perhaps HIV-1 Rev function via this complex. In sum-
mary, our identification of 12 multi-protein complexes
which contain CDK9/CCNT1 reveals considerable
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as the basis for future research on molecular mechanisms
involved in HIV-1 gene expression and replication.
Conclusions
Our results identified a very large potential complexity
in the biological functions of CDK9 and CCNT1. Our
results suggest that at least five newly identified multi-
protein complexes contain both CDK9 and CCNT1 and
may reduce the amount of these proteins available for
Tat function.
Methods
Cell culture and activation
TZM-bl, HeLa, and 293T cells were cultured in DMEM
supplemented with 10% fetal bovine serum (FBS) and
1% penicillin-streptomycin. Jurkat CD4+ T cells and Jur-
kat 2D10 cells were cultured in RPMI supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin. 2D10 cells were activated using Dynabeads
CD3/CD28 T cell expander beads (Invitrogen) according
to the manufacturer’s protocol.
SiRNA and plasmid transfections
Control and siRNAs against individual subunits of CCAPs
were purchased from Santa Cruz Biotechnology, CA as
pools of three target specific siRNAs. The pool of three
siRNAs was specific for distinct target sites in the tran-
script of the protein to be depleted. This approach has an
advantage over using individual siRNAs since depletion of
target protein could be achieved with lower amount of
siRNA reducing the risk of off-target effects. SiRNAs (10–
30 pmol) was delivered into TZM-bl, HeLa, Jurkat or
2D10 cells by either a reverse or traditional transfection
method. For reverse transfections, TZM-bl or HeLa cells
were seeded in 10 cm plates at 24 hours before experi-
ment. On the day of transfection, the cells were collected
by trypsinization and suspended in DMEM with 10% FBS
and no antibiotics (50,000 cells/ well/sample) in 24 well
tissue culture plates. Transfection was carried out using
Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s protocol. SiRNAs and Lipofectamine
RNAiMAX were diluted in Opti-MEM1 and mixed to-
gether. The siRNA-transfection reagent mixture was incu-
bated at room temperature (RT) for 20 minutes and
added to the cells. For traditional transfections, the proto-
col used was as described above except that TZM-bl or
HeLa cells were seeded in 24 well tissue culture plates
(50,000 cells/well/sample) at 18 hours before experiments.
Jurkat cells and 2D10 cells were seeded the same day of
experiment and transfected with siRNAs as described
above.
In experiments with TZM-bl cells in 24 well tissue cul-
ture plates, cells were transfected for 48 hours with 50ng of pFLAG- wild type HIV-1 Tat (wtTat) or pFLAG-
pro18IS-HIV-1 Tat (mTat) using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instruc-
tions. In other plasmid transfection experiments carried
out in HeLa cells, 500 ng HIV-1 LTR reporter plasmid
and 50 ng Tat expression plasmid were transfected as
described for TZM-bl cells. In these experiments, cells
were also transfected with 500 ng pNF-kB-Luc and 50 ng
pcDNA empty vector (pCMV parent) ensuring equal
amounts of DNA were transfected.
Immunoblot and immunoprecipitation analysis
Cells were lysed with EBCD buffer (50mM Tris–HCl,
pH 8.0, 120mM NaCl, 0.5% NP-40, 5mM dithiothreitol)
containing protease inhibitor cocktail (Sigma). Immuno-
blotting was performed as described previously [4].
TTF2, FBXO11, WRNIP1, TPR, PPP1R10, Hsp70 and β-
actin were probed using antibodies against TTF2
(Abcam, 1:1000), FBXO11 (Bethyl Labs, 1:2000),
WRNIP1 (Santa Cruz, 1:1000), TPR (Santa Cruz, 1:
1000), PPP1R10 (Abcam, 1: 1000), and β-actin (Sigma)
(1:5000), respectively. Immunoblots were quantified
using Image J software [73]. Immunoprecipitation was
carried out as described previously [65,74].
Luciferase reporter assays
Cells were washed with sterile PBS and cell lysates pre-
pared with Cell Culture Lysis Buffer (Promega). Cell
lysates were analyzed for Luciferase activity using Luci-
ferase Assay Kit (Promega) according to manufacturers’
protocol. Luciferase assay products were measured using
a luminometer (Turner). Total protein in the lysates was
estimated using a Bradford assay (Bio-Rad) and used to
normalize the Luciferase readings.
Flow cytometry analysis
2D10 cells were examined for GFP expression on a BD
Fortessa flow cytometer. 10,000 events were collected
and the data analysed using BD FACS Diva software. For
visualization of the data as a dot plot, PE was used as a
placeholder fluorophore.
Additional file
Additional file 1: Figure S1. Depletion of combinations of CCAPs has
an additive effect on HIV-1 Tat function in TZM-bl cells. TZM-bl cells were
transfected with control siRNA or combination of the indicated siRNAs
for 48 hours. Cells were then transfected with HIV-1 Tat (wtTat) and 24
hours later cell lysates were prepared and examined for Luciferase
expression. Luciferase expression values were normalized to amount of
total cellular protein. A representative experiment from three
independent experiments is shown. Statistical significance was estimated
using t-test. (* p≤ 0.05 and ** p< 0.005).
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